In the treatment of gastric cancers, direct adoptive transfer of NK cells or enhancement of NK cell and ILC1 anti-tumor function by targeting the inhibitory receptors of NK cells and ILC1s such as NKG2A may serve as a potential therapeutic strategy, which has been under investigation in colorectal cancers [39]. This evidence concerns the gene KLRC1 and neoplasm.